[1] Hans PH,Steven FH,Timothy JL,et al.Assessment of riboso-mal large-subunit D1-D2,internal transcribed spacer 1,and in-ternal transcribed spacer 2 regions as targets for molecular identi-fication of medically important Aspergillus species[J]. J Clin Microbiol,2005,43 (5):2092-2103.
[2] Christopher JL,Andrew MB,Grace C,et al.Molecular identifica-tion of unusual pathogenic yeast isolates by large ribosomal sub-unit gene sequencing:2 years of experience at the United King-dom Mycology Reference Laboratory[J]. J Clin Microbiol,2007,45(4):1152-1158.
[3] Gassone M,Pietro S,Mondello F,et al.Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism[J]. J Clin Mi-crobiol,2003,41(11):5340-5343.
[4] Han XY,Tarrand JJ,Escudero E.Infections by the yeast kodomaea (Pichia) ohmeri:two cases and literature review[J]. Eur J Clin Microbiol Infect Dis,2004,23 (2):127-130.
[5] Pfaller MA,Diekema DJ,Messer SA,et al.in vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp.,including 157 fluconazole-resistant isolates[J]. Antimicrob Agents Chemother,2003,47(3):1068-1071.
[6] Wisplinghoff H,Bischoff T,Tallent SM,et al.Nosocomial blood-stream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis,2004,39(3):309-317.
[7] Frank M,Gur E,Givon-Lavi N,et al.Nosocomial bloodstream infections in children and adolescents in southern Israel:a 10-year prospective study (1992-2001)[J]. Stand J Infect Dis,2005,37(3):177-183.
[8] Wu CJ,Lee HC,Lee NY,et al.Predominance of Gramnegative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Tai-wan,1996-2003[J]. J Microbial Immunol Infect,2006,39(2):135-143.
[9] Pfaller MA,Diekema DJ,Gibbs DL,et al.Resultsfrom the AR-TEMIS DISK global antifungal surveillance study,1997 to 2005:an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voricnnazole determined by CLSI standardized disk diffusion testing[J]. J Clin Microbiol,2007,45(6):1735-1745.
[10] Sandven P,Bevanger L,Digranes A,et al.Candidemia in Nor-way(1991 to 2003):results from a nationwide study[J]. J Clin Micmbiol,2006,44 (6):1977-1981.
[11] Ruan SY,Hsoeh PB.Invasive candidiasis:an overview from Tai-wan[J]. J Formos Med Assoc,2009,108(6):443-451.
[12] St-Germain G,Laverdiere M,Pelletier R,et al.Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec:Report on 453 cases between 2003 and 2005[J]. Can J Infect Dis Med Microbiol,2008,19(1):55-62.
[13] Pfaller MA,Boyken L,Hollis RJ,et al.in vitrosusceptibility of invasive isolates of Candida spp.to anidulafungin,caspofungin,and micafungin:six years of global surveillance[J]. J Clin Mi-crobiol,2008,46(1):150-156.
[14] Sobel JD,Wiesenfeld HC,Martens M,et al.Maintenance flu-conazole therapy for recurrent vulvovaginal candidiasis[J]. New Engl J Med,2004,351(9):876-883.
[15] Mohanty S,Xeas I,Hasan F,et al.Prevalence & susceptibilityto fluconazole of Candida species causing vuivovaginitis[J]. In-dian J Med Res,2007,126(3):216-219.
[16] Tan TY,Tan AL,Tee NW,et al.A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals[J]. Ann Acad Med Singapore,2008,37(10):835-840.
[17] Pfaller MA,Diekema DJ.Rare and emerging opportunistic fun-gal pathagens:concern for resistance beyond Candida albicansand Aspergillus fumigatus[J]. J Clin Microbiol,2004,42(10):4419-4431.
[18] Lortholary O,Dannanui E,Raonx D,et al.in vitro susceptibil-ity to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method d the European Committee on Antimicrobial Susceptibility Testing[J]. Antimi-crob Agents Chemother,2007,51(9):3378-3380.
[19] Almirante B,Rodriguez D,Park BJ,et al.Epidemiology and predictors of mortality in cases of Candida bloodstream infec-tion:results from populatian-based surveillance,barcelona,Spain,from 2002 to 2003[J]. J Clin Microbiol,2005,43(4):1829-1835.
[20] Steenbergen JN,Casadevall A.The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans.Microbes Infect,2003,5(7):667-675.
[21] Datta K,Jain N,Sethi S,et al.Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India:a need for care[J]. J Antimicrob Chemother,2003,52(4):683-686.
[22] Souza LK,Fernandes Ode F,Kobayashi CC,et al.Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city,Goias,Brazil[J]. Rev Inst Med Trop Sao Paulo,2005,47(5):253-256.
[23] Sar B,Moncliy D,Vann M,et al.Increasing in vitroresistance to fluconazole in Cryptococcus neoformans Cambodian isolates:April 2000 to March 2002[J]. J Antimicrob Chemother,2004,54(2):563-565.
[24] Pfaller MA,Diekema D J,Gibbs DL,et al.Results from the ARTEMIS DISK global antifungal surveillance study,1997 to 2007:10.5-yesr analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing[J]. J Clin Microbiol,2009,47(1):117-123.
[25] Padhye AA,Verghese S,Ravichandran P,et al.Trichosporon loubieri infection in a patient with adult polycystic kidney dis-ease[J]. J Clin Microbiol,2003,41(1):479-482.
[26] Araujo Ribeiro M,Alastruey-lzqnierdo A,Gomez-Lopez A,et al.Molecular identification and susceptibility testing of Trichos-poron isolates from a Brazilian hospital[J]. Rev Iberoam Mi-col,2008,25(4):221-225.
[27] Tuon FF,Costa SF.Rhodotorula infection.A systematic review of 128 cases from literature[J]. Bey Iberoam Micol,2008,25(3):135-140.
[28] Gomez-Lopes A,Mellado E,Rodriguez-Tudela JL,et al.Sus-ceptibility profile of 29 clinical isolates of Rhodotorula spp.and literature review[J]. J Antimicrob Chemother,2005,55 (3):312-316.
[29] Diezmann S,Dietrich FS.Saccharomyces cerevisiae:population divergence and resistance to oxidative stress in clinical,domesti-cated and wild isolatos[J]. PLoS ONE,2009,4(4):e5317.
[30] Lass-Florl C,Mayr A,Perkhofer S,et al.Activities of antifun-gal agents against yeasts and filamentous fungi:asasesment ac-cording to the methodology of the European Committee on Anti-microbial Susceptibility Testing[J]. Antimicrob Agents Che-mother,2008,52(10):3637-3641. |
